RT Journal Article
SR Electronic
T1 Fasting alters the gut microbiome with sustained blood pressure and body weight reduction in metabolic syndrome patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.23.20027029
DO 10.1101/2020.02.23.20027029
A1 András Balogh
A1 Hendrik Bartolomaeus
A1 Ulrike Löber
A1 Ellen G. Avery
A1 Nico Steckhan
A1 Lajos Markó
A1 Nicola Wilck
A1 Ibrahim Hamad
A1 Urša Šušnjar
A1 Anja Mähler
A1 Christoph Hohmann
A1 Holger Cramer
A1 Gustav Dobos
A1 Till Robin Lesker
A1 Till Strowig
A1 Ralf Dechend
A1 Danilo Bzdok
A1 Markus Kleinewietfeld
A1 Andreas Michalsen
A1 Dominik N. Müller
A1 Sofia K. Forslund
YR 2020
UL http://medrxiv.org/content/early/2020/02/25/2020.02.23.20027029.abstract
AB Periods of fasting and refeeding may reduce cardiometabolic risk elevated by Western diet. We show that in hypertensive metabolic syndrome (MetS) patients (n=35), a 5-day fast followed by a modified DASH diet (Dietary Approach to Stop Hypertension) reduced systolic blood pressure (SBP), antihypertensive medication need, and body-mass index (BMI) at three months post intervention compared to a modified DASH diet alone (n=36). Fasting altered the gut microbiome, impacting bacterial taxa and gene modules associated with short-chain fatty acid production. Cross-system analyses revealed a positive correlation of circulating mucosa-associated invariant T (MAIT) cells, non-classical monocytes and CD4+ effector T cells with SBP. Furthermore, regulatory T cells (Tregs) positively correlated with BMI and weight. Machine learning could predict sustained SBP-responsiveness within the fasting group from baseline immunome data, identifying CD8+ effector T cells, Th17 cells and Tregs as important contributors to the model. The high-resolution multi-omics data highlights fasting as a promising non-pharmacological intervention in MetS.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02099968Funding StatementThis work was supported by a grant of the Corona-Stiftung im Deutschen Stiftungszentrum, Essen, Germany. NW is supported by a grant from the Corona-Stiftung. MK and NW were supported by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (MK: 640116; NW: 852796). MK was further supported by a SALK-grant from the government of Flanders, Belgium and by an Odysseus-grant of the Research Foundation Flanders (FWO), Belgium. The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Projektnummer 394046635 - SFB 1365 and the DZHK (German Centre for Cardiovascular Research, 81Z1100101) supported DNM, HB, NW, SF, and LM. NW is participant in the Clinician Scientist Program funded by the Berlin Institute of Health (BIH).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.